Bremelanotide Brand Name– VYLEESI
What is Bremelanotide
Bremelanotide is an injectable melanocortin receptor agonist. It is administered subcutaneously and indicated in premenopausal females for the treatment of Hypoactive Sexual Desire Disorder (HSDD), or low sexual desire.
It has a unique mechanism of action that helps activate brain pathways that are involved in normal sexual responses.
Safety and efficacy were established in premenopausal females 19 to 56 years of age with HSDD that causes marked distress or interpersonal difficulty and is NOT due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.
Bremelanotide is not indicated for the treatment of HSDD in postmenopausal women, males, or to enhance sexual performance.
In clinical trials, about 25% of patients treated with bremelanotide had an increase of 1.2 or more in their sexual desire score (scored on a range of 1.2 to 6, with higher scores indicating greater sexual desire) compared to approximately 17% of those who took placebo.
Bremelanotide is used “as needed” prior to anticipated sexual activity; women will not have to use the drug on a daily basis.
Bremelanotide was FDA-approved in June 2019.
Indications
- hypoactive sexual desire disorder
For the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) (also known as female sexual interest/arousal disorder)
Side Effects
- abdominal pain
- arthralgia
- cough
- diarrhea
- dizziness
- fatigue
- flushing
- headache
- hepatitis
- hot flashes
- hypertension
- injection site reaction
- melasma
- myalgia
- nasal congestion
- nausea
- paresthesias
- rhinorrhea
- skin hyperpigmentation
- vomiting
Contraindications
- breast-feeding
- cardiac disease
- children
- contraception requirements
- geriatric
- hepatic disease
- hypertension
- infants
- nausea/vomiting
- postmenopausal females
- pregnancy
- renal failure
- renal impairment
- skin hyperpigmentation
Interactions
- Bupropion; Naltrexone
- Naltrexone
